Alterity Therapeutics Ltd

ATH

Company Profile

  • Business description

    Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

  • Contact

    350 Collins Street
    Level 14
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    10

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,963.5029.200.33%
CAC 407,800.8833.70-0.43%
DAX 4023,970.36247.14-1.02%
Dow JONES (US)44,766.96134.96-0.30%
FTSE 1009,081.4438.87-0.43%
HKSE25,562.13173.780.68%
NASDAQ21,148.7740.450.19%
Nikkei 22540,998.27457.96-1.10%
NZX 50 Index12,910.7457.280.45%
S&P 5006,379.818.83-0.14%
S&P/ASX 2008,697.7030.800.36%
SSE Composite Index3,597.944.280.12%

Market Movers